Article | Published:

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Abstract

Inhibitory receptors have been proposed to modulate the in vivo cytotoxic response against tumor targets for both spontaneous and antibody-dependent pathways1. Using a variety of syngenic and xenograft models, we demonstrate here that the inhibitory FcγRIIB molecule is a potent regulator of antibody-dependent cell-mediated cytotoxicity in vivo, modulating the activity of FcγRIII on effector cells. Although many mechanisms have been proposed to account for the anti-tumor activities of therapeutic antibodies, including extended half-life, blockade of signaling pathways, activation of apoptosis and effector-cell-mediated cytotoxicity, we show here that engagement of Fcγ receptors on effector cells is a dominant component of the in vivo activity of antibodies against tumors. Mouse monoclonal antibodies, as well as the humanized, clinically effective therapeutic agents trastuzumab (Herceptin®) and rituximab (Rituxan®), engaged both activation (FcγRIII) and inhibitory (FcγRIIB) antibody receptors on myeloid cells, thus modulating their cytotoxic potential. Mice deficient in FcγRIIB showed much more antibody-dependent cell-mediated cytotoxicity; in contrast, mice deficient in activating Fc receptors as well as antibodies engineered to disrupt Fc binding to those receptors were unable to arrest tumor growth in vivo. These results demonstrate that Fc-receptor-dependent mechanisms contribute substantially to the action of cytotoxic antibodies against tumors and indicate that an optimal antibody against tumors would bind preferentially to activation Fc receptors and minimally to the inhibitory partner FcγRIIB.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Bolland, S. & Ravetch, J.V. Inhibitory pathways triggered by ITIM-containing receptors. Adv. Immunol. 72, 149–177 (1999).

  2. 2

    Clynes, R.A., Tekechi, Y., Moroi, Y., Houghton, A. & Ravetch, J.V. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 95, 652 (1998).

  3. 3

    Hudziak, R. et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor Mol. Cell Biol. 9, 1165 ( 1989);

  4. 4

    Taji, H. et al. Growth inhibition of CD20 positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn. J. Cancer Res. 89, 748 (1998).

  5. 5

    Masui, H., Moroyama, T. & Mendelsohn, J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes Cancer Res. 46, 5592 (1986);

  6. 6

    Waldmann, T.A. Lymphokine receptors: a target for immunotherapy of lymphomas. Ann. Oncol. Supp. 13, 5, 1– 45 (1994).

  7. 7

    Tutt, A.L. et al. Monoclonal antibody therapy of a B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J. Immunol. 161, 3176 (1998).

  8. 8

    Pegram, M.D. et al. Phase II study of receptor enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2.neu overexpressing metastatic breast cancer refractory to chemotherapy treatment J. Clin. Oncol. 16, 2659 (1998)

  9. 9

    Carter, P.L. et al. Humanization of an anti-p185HER2 antibody for human cancer treatment, Proc. Natl. Acad. Sci. USA 89, 4285 (1992).

  10. 10

    Leget, G.A. & Czuczman, M.S. Use of Rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 10, 548– 551 (1998)

  11. 11

    Kopreski, M., Lipton, A., Harvey, H.A. & Kumar, R. Growth inhibition of breast cancer cell lines by combinations of anti-p185 monoclonal antibody and cytokines. Anticancer Res. 16, 433– 436 (1996).

  12. 12

    Lewis, G.D. et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37, 255–263 (1993).

  13. 13

    Shan, D., Ledbetter, J.A. & Press, O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91, 1644–1652 (1998).

  14. 14

    Takai, T., Li., M., Sylvestre, D., Clynes, R. & Ravetch, J.V. FcR γ chain deletion results in pleiotropic effector cell defects. Cell 76, 519– 529 (1994).

  15. 15

    Takai, T., Ono, M, Hikida, M., Ohmori, H. & Ravetch, J.V. Augmented humoral and anaphylactic responses in Fc_RIIB deficient mice. Nature 379, 346– 349 (1996).

  16. 16

    Funakoshi, S., Longo, D.L. & Murphy, W.J. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. J. Immunother. 19, 93–101 (1996).

  17. 17

    Fan, Z., Masui, H., Altas, I. & Mendelsohn, J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies Cancer Res. 53, 4322–4328 (1993)

  18. 18

    Baselga, J., Norton, L., Albanell, J., Kim, Y.M. & Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the anti-tumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825–2831 (1998).

  19. 19

    Liu, J., Lester, P., Builder, S. & Shine, J. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34, 10474– 10482 (1995).

Download references

Acknowledgements

We thank D. White for his technical expertise, C. Ritter for her administrative assistance and R. Steinman and M. Nussenzweig for their comments on the manuscript. These studies were supported by grants from the National Institutes of Health, Cancer Research Institute and Genentech.

Author information

Correspondence to Jeffrey V. Ravetch.

Rights and permissions

Reprints and Permissions

About this article

Further reading

Figure 1: Passive protection from pulmonary metastasis is increased considerably in FcγRIIB-deficient mice.
Figure 2: Anti-tumor activities of 4D5, trastuzumab and rituximab require activation Fcγ receptors.
Figure 3: Anti-breast tumor activity of 4D5 and trastuzumab is enhanced FcγRIIB-deficient mice.
Figure 4: In vitro and in vivo properties of the D255A mutant antibody.